A study of ENV1105 for the treatment of diabetic macular oedema (DME).
Phase of Trial: Phase I
Latest Information Update: 31 Mar 2016
At a glance
- Drugs Dexamethasone (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions
- 31 Mar 2016 New trial record
- 23 Mar 2016 According to an Envisia Therapeutics media release, the company expects to initiate this phase I trial of ENV1105 for the treatment of diabetic macular oedema in the first half of 2017.